FCGR1A and autoimmune thrombocytopenic purpura: In this study, we found that ONX-0914 treatment down-regulate FcγRI (CD64) expression in the monocytes of a murine model of passive ITP, and decreased the levels of FcγRIII (CD16) in the monocytes of ITP patients.